Takeda clinical trial

Business news, market intelligence, and global industry analysis.

The Latest

Representative image illustrating a drone flying over California as reports reveal that Iran allegedly considered a surprise drone strike on targets in the state, according to a Federal Bureau of Investigation intelligence bulletin disclosed during the ongoing United States–Iran conflict.

Iran planned surprise drone strike on California, FBI bulletin reveals

Palantir Technologies (NASDAQ: PLTR) expands Asia enterprise push through LG CNS partnership

What LG CNS and Palantir’s new partnership means for the future of industrial AI adoption

Representative image of the United States Strategic Petroleum Reserve and oil infrastructure as the Trump administration authorises a 172 million barrel SPR drawdown while 32 International Energy Agency nations coordinate the largest emergency oil release in history to stabilise global crude markets.

Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release

IBM Corporation and Lam Research Corporation launch five-year collaboration to enable sub-1nm semiconductor logic scaling

The sub-1nm race is heating up and IBM and Lam Research just made their move

Takeda’s oveporexton Phase 3 trials show broad success in narcolepsy type 1, paving way for 2025 FDA submission

Takeda announces pivotal Phase 3 trial results for oveporexton (TAK-861), showing statistically significant improvements in narcolepsy type 1 symptoms. Regulatory filings planned.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

July 14, 2025